Technology, Healthcare Jun 24, 2022 01:59 PM (GMT+8) · EqualOcean
According to scidev.net daily on the 24th, the reporter learned from OPEC that the 0.01% low concentration atropine developed by the company for the prevention and control of myopia in children and adolescents has obtained the preparation license for medical institutions, but has not been sold so far. Near midday on the 24th, affected by the rumor that the Internet hospital would restrict the issuance of atropine, the ophthalmology sector plunged rapidly, and the share price of Xingqi ophthalmic once plummeted by more than 17%.

This text is a result of machine translation.

Related companies：